hDomino: A Potential Drug Target and Biomarker for the Treatment of Epilepsy

Target Name: EP400

NCBI ID: G57634

EP400

hDomino: A Potential Drug Target and Biomarker for the Treatment of Epilepsy

Epilepsy is a chronic and debilitating neurological disorder that affects millions of people worldwide. Despite being one of the most common reasons for hospitalization, it remains a refractory disease with a high treatment failure rate. The introduction of new treatments for epilepsy has been limited due to the lack of effective drug targets. However, the identification of potential drug targets and biomarkers can lead to the development of new treatments with improved efficacy and safety. In this article, we discuss hDomino, a potential drug target and biomarker for the treatment of epilepsy.

hDomino is a protein that is expressed in the cerebral cortical regions of the brain. It is involved in the regulation of neuronal excitability and is a known modulator of pain perception. Studies have shown that hDomino is highly expressed in the brain and that it is involved in the pathophysiology of epilepsy.

One of the key features of hDomino is its role in the regulation of neuronal excitability. hDomino is a known modulator of the voltage-gated sodium channel (VGSC), which is responsible for the rapid depolarization of the neuron that occurs during an action potential. Studies have shown that hDomino can inhibit the activity of VGSC, which can lead to a reduction in neuronal excitability. This reduction in neuronal excitability can be a potential therapeutic approach for the treatment of epilepsy.

Another feature of hDomino is its role in the regulation of pain perception. Studies have shown that hDomino is involved in the regulation of pain sensitivity and that it can modulate the activity of a protein called TRPV1. TRPV1 is a G protein-coupled receptor that is involved in the sensation of pain. The inhibition of hDomino by hDomino antagonists has been shown to reduce pain sensitivity. This suggests that hDomino may be a potential biomarker for the treatment of epilepsy.

In addition to its role in the regulation of neuronal excitability and pain perception, hDomino is also involved in the regulation of cell survival. Studies have shown that hDomino can modulate the activity of the protein Bcl-2, which is involved in the regulation of cell survival. The inhibition of hDomino by hDomino antagonists has been shown to increase the activity of Bcl-2, which can lead to increased cell survival. This increased cell survival can contribute to the development of epilepsy.

The identification of a potential drug target and biomarker for the treatment of epilepsy is an exciting development in the field of neurology. The development of new treatments for epilepsy will require the use of a combination of approaches, including the identification of potential drug targets and biomarkers. hDomino is a potential drug target and biomarker for the treatment of epilepsy due to its involvement in the regulation of neuronal excitability, pain perception, and cell survival. Further studies are needed to determine the efficacy and safety of hDomino as a potential treatment for epilepsy.

Protein Name: E1A Binding Protein P400

Functions: Component of the NuA4 histone acetyltransferase complex which is involved in transcriptional activation of select genes principally by acetylation of nucleosomal histones H4 and H2A. This modification may both alter nucleosome - DNA interactions and promote interaction of the modified histones with other proteins which positively regulate transcription. May be required for transcriptional activation of E2F1 and MYC target genes during cellular proliferation. The NuA4 complex ATPase and helicase activities seem to be, at least in part, contributed by the association of RUVBL1 and RUVBL2 with EP400. May regulate ZNF42 transcription activity. Component of a SWR1-like complex that specifically mediates the removal of histone H2A.Z/H2AZ1 from the nucleosome

The "EP400 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EP400 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets